Veracyte VCYT Biopharmaceutical and other revenue — Other cost

Other product segments

Similar metrics at other companies

LHBiopharma Laboratory Services — Other Cost and Expense, Operating

$89.7M-0.3%

BMRNOther operating expenses

$3.96M+303%

PFEBiopharma — Other Nonoperating Income (Expense)

$116M+48.7%

BDXBioPharma Systems — Segment Other Operating Expense (Income), net as a Percent of Revenues

0%—

BDXBioPharma Systems — Other Operating Income

$0—

UTHROther — Cost of Sales

$12.1M+102%

Questions, answered.

What is Veracyte's biopharmaceutical and other revenue — other cost?

Veracyte (VCYT) reported biopharmaceutical and other revenue — other cost of $8K in Q1 2026.

How has Veracyte's biopharmaceutical and other revenue — other cost changed year-over-year?

Veracyte's biopharmaceutical and other revenue — other cost decreased by 99.2% year-over-year, from $1.04M to $8K.

What is the long-term trend for Veracyte's biopharmaceutical and other revenue — other cost?

Over 3 years (2022 to 2025), Veracyte's biopharmaceutical and other revenue — other cost has grown at a -29.0% compound annual growth rate (CAGR), from $9.3M to $3.33M.

What does biopharmaceutical and other revenue — other cost mean?

This metric encompasses miscellaneous operational expenses directly tied to the biopharmaceutical segment that are not classified as direct labor or facility allocations. It is used to monitor the variable overhead and incidental costs associated with maintaining research partnerships.